Literature DB >> 26843718

Ledipasvir with sofosbuvir.

.   

Abstract

Entities:  

Year:  2015        PMID: 26843718      PMCID: PMC4674024          DOI: 10.18773/austprescr.2015.078

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


× No keyword cloud information.
  5 in total

1.  Therapy for hepatitis C--the costs of success.

Authors:  Jay H Hoofnagle; Averell H Sherker
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

2.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

3.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

4.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

5.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

  5 in total
  4 in total

1.  Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.

Authors: 
Journal:  Aust Prescr       Date:  2016-05-20

Review 2.  Sofosbuvir with velpatasvir.

Authors: 
Journal:  Aust Prescr       Date:  2017-08-09

3.  Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.

Authors:  Rameez Hassan Pirzada; Muhammad Haseeb; Maria Batool; MoonSuk Kim; Sangdun Choi
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 4.  Elbasvir/grazoprevir.

Authors: 
Journal:  Aust Prescr       Date:  2017-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.